BLOOD SUBSTITUTE EFFICACY ENDPOINTS WILL EVOLVE THROUGH CLINICAL EXPERIENCE, FDA HEMATOLOGY HEAD SUGGESTS; RED CELL SUBSTITUTE WORKSHOP FINDS LITTLE CONSENSUS
Blood substitute efficacy endpoints will evolve through clinical experience, FDA Center for Biologics Evaluation & Research Hematology Division Director Joseph Fratantoni, PhD, suggested at an agency cosponsored workshop on criteria for efficacy of red cell substitutes held at the National Institutes of Health Jan. 11.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth